Pharmacosmos
CompanyDenmarkFounded 1965
Pharmacosmos develops 7 assets, the furthest approved (Ferric Derisomaltose in Anemia, Iron-Deficiency). Mostly small molecule and other acting on CDK6 and CDK4; based in Denmark, founded in 1965.
- 7
- Assets
- Furthest stage
- Approved
- 31
- Trials
- 8
- Signals
Pipeline
7Replenishes iron stores to correct iron deficiency and support oxygen transport and cellular energy metabolism.
Approved, Other, Anemia, Iron-Deficiency, iron deficiency (Phase 3)
Transiently inhibits CDK4/6 to protect hematopoietic stem and progenitor cells from chemotherapy-induced damage.
Approved, Small molecule, CDK6, CDK4, myelosuppression, extensive stage small cell lung cancer (Phase 3)
Chelates iron to treat transfusional iron overload.
Phase 2, Small molecule, transfusion-dependent thalassemia, transfusional iron overload
4 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
113 trials
In the full profile
- Evidence behind the mechanisms4
- Trials43
- People17
- Signals18
- Similar companies6
Papers
ADA Scientific Sessions 2025 abstract, Jun 13, 2025